Rakesh Jhunjhunwala buys 50 lakh shares of this firm, stock gains 5%

The small cap share gained up to 4.85% to Rs 187.90 against previous close of Rs 179.20 on BSE

Share price of Dishman Carbogen Amcis was trading higher in early trade after ace investor Rakesh Jhunjhunwala and his wife Rekha Jhunjhunwala bought 3.18% stake in the firm in June quarter. Jhunjhunwala and his wife bought 25 lakh shares each in the company.

Dishman Carbogen Amcis share gained up to 4.85% to Rs 187.90 against previous close of Rs 179.20 on BSE. The stock opened with a gain of 2.3% at Rs 183.40 today. The share has lost 14.14% in one year and gained 111.95% since the beginning of this year.

In a month, the small cap share has risen 47%. Total 0.55 lakh shares changed hands amounting to turnover of Rs 1.03 crore. Market cap of the firm rose to Rs 2,915 crore. The share hit 52 week high of Rs 218.30 on September 29, 2019 and 52-week low of Rs 46.45 on March 30, 2020.

The firm is engaged in the process of research and development to late-stage clinical and commercial manufacturing. It operates through nine manufacturing sites in Europe, India, China and Saudi Arabia.

Apart from Dishman Carbogen, the big bull raised stake and bought shares in other firms in Q1 of the current fiscal. He raised stake in pharma firm Jubilant Life Sciences in Q1. Jhunjhunwala held 81,45,800 shares in the firm in last quarter against 70,25,000 shares held in the March quarter. In three separate accounts, Jhunjhunwala had 31,25,800 shares, 25,20,000 shares and 25,00,000 shares in Q1.

In March quarter, the ace investor held 43,72,222 and 26,52,778 shares of the company in two different accounts.

The ace investor bought 1.05 per cent stake or 1.25 crore shares of Indian Hotels in Q1. He was not among the key shareholders of the company earlier, data available with Ace Equity show.

In Rallis India, Jhujhunwala raised his stake by 0.38 per cent during June quarter.

Jhunjhunwala purchased an additional 7.25 lakh equity shares to raise his stake to 10.31 per cent during the April-June period. He holds shares in the Tata Group company through his two accounts-Rakesh Radheshyam Jhunjhunwala (7.64 per cent) and Rakesh Jhunjhunwala (2.67 per cent), shareholding pattern on BSE showed.

Jhunjhunwala held 1,93,05,820 shares (or 9.93 per cent stake) in the agrochemicals firm at the end of March 2020 against 1,90,30,820 shares at the end of December 2019.

In Federal Bank too, Jhunhjunwala bought an additional 20 lakh shares in the quarter ended June 2020. In June quarter, Jhunhjunwala's total holding in the bank stood at 3.18 percent in the quarter ended June 2020 against 3.08 percent in March 2020.In last quarter, the big bull held 6.23 crore shares against 6.03 crore shares held by him for quarter ended March.

Comments

Panacea Biotech shares hit 5% upper circuit after dengue vaccine completes phase I & II study

DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes, the company has said in an exchange filing. Panacea Biotech share price hit 5 percent upper circuit on the BSE on September 24 after the company completed phases I and II study of its dengue vaccine candidate DengiAIl. "Panacea Biotec Ltd. is delighted to announce the successful completion of its Phase I/II study to evaluate the safety and immunogenicity of its vaccine, DengiAll, a single-dose liveattenuated tetravalent vaccine," the company said in an exchange filing. Live-attenuated vaccines contain weakened bacteria or viruses that trigger an immune response but do not cause disease. The company said DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes. DengiAIl has been found to be safe and well-tolerated with no serious adverse effects, the company said. After a single-dose, more than 80 percent of the participants ...

Brokerages place bets on Titan, see double-digit upside in the stock

Titan can get benefits from the strong market share in the jewellery and wrist watches segment, mainly driven by a wide range of product portfolio catering mainly to the premium and value-added designer jewellery segment. After three consecutive sessions of losses, shares of Titan Company rose over a percent in morning trade on BSE on September 23. The company was dealt a severe blow by COVID-19 as the pandemic triggered strict lockdowns completely battered the retail sector. In the calendar year so far, shares of this one of the largest, most efficient and profitable specialty retailer in India are 7 percent down. The company reported a net standalone loss of Rs 270 crore for the quarter ended June 2020 as the COVID-19 pandemic hit business. The loss was higher than a CNBC-TV18 poll estimate of Rs 175 crore. Standalone revenue during the quarter declined 62.3 percent year-on-year to Rs 1,862 crore compared to the corresponding period last fiscal. Light at the end ...

Check Chemcon Speciality Chemicals IPO allotment status in four simple steps

Equity shares will get credited into the accounts of eligible investors by September 30 and the listing of equity shares will be on October 1, 2020. Chemcon Speciality Chemicals, the manufacturer for pharmaceutical and oilfields industries, is expected to announce the basis of allotment early next week. As per the schedule provided by the company, the finalisation of the basis of the allotment will be done by September 28 and the initiation of refunds or unblocking of funds from ASBA account will take place on September 29. Equity shares will get credited to the accounts of eligible investors by September 30 and the listing will be on October The IPO comprised a fresh issue of Rs 165 crore and an offer for sale of Rs 153 crore by promoters. The company will utilise fresh issue proceeds for expansion of manufacturing facility, working capital requirements, and general corporate purposes. Chemcon manufactures specialised chemicals, such as Hexamethyldisilazane (HMDS) and Chloromethyl Iso...

SD Solutions

Search This Blog